Circulating orexin changes during withdrawal are associated with nicotine craving and risk for smoking relapse

Research output: Contribution to journalArticle

Abstract

We examined the extent to which orexin measured during smoking and the early phase of abstinence was related to craving, withdrawal, stress hormones, and risk for smoking relapse in men and women. Considering its role in modulating nicotine-related reward, we predicted that a reduction in circulating orexin during withdrawal would be associated with increased craving and risk for smoking relapse. Two hundred and eighty five participants provided biological samples and self-report information to identify predictors of smoking relapse. All participants attended two laboratory sessions, which were before and after a period of required abstinence from smoking. After quitting, participants also attended four weekly sessions to track smoking relapse. Only smokers who relapsed within the follow-up period exhibited reduced orexin levels during the initial withdrawal period; ACTH, but not craving nor cortisol, increased across the abstinence period for successful abstainers but not for relapsers. Sex differences in orexin and craving or withdrawal associations also emerged. Adding sex, HPA hormones, and self-reported measures of craving and withdrawal as potential mediators had minimal effects on the above abstinence and orexin effects. These results provide the first evidence that circulating orexin may be a useful marker of risk for relapse; and sex, adrenal hormones, and self-reported craving and withdrawal were not mediators of this effect. The results point to a promising pathway to investigate objective biological markers for craving and smoking relapse and highlight the complexity of the neurobiology of relapse.

Original languageEnglish (US)
Pages (from-to)743-753
Number of pages11
JournalAddiction Biology
Volume24
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Nicotine
Smoking
Recurrence
Gonadal Steroid Hormones
Neurobiology
Craving
Reward
Sex Characteristics
Adrenocorticotropic Hormone
Self Report
Hydrocortisone
Biomarkers
Hormones

Keywords

  • craving
  • gender
  • mood
  • orexin
  • relapse
  • smoking

PubMed: MeSH publication types

  • Journal Article

Cite this

@article{020ed6dd7a59412e8c336d2011b23ef4,
title = "Circulating orexin changes during withdrawal are associated with nicotine craving and risk for smoking relapse",
abstract = "We examined the extent to which orexin measured during smoking and the early phase of abstinence was related to craving, withdrawal, stress hormones, and risk for smoking relapse in men and women. Considering its role in modulating nicotine-related reward, we predicted that a reduction in circulating orexin during withdrawal would be associated with increased craving and risk for smoking relapse. Two hundred and eighty five participants provided biological samples and self-report information to identify predictors of smoking relapse. All participants attended two laboratory sessions, which were before and after a period of required abstinence from smoking. After quitting, participants also attended four weekly sessions to track smoking relapse. Only smokers who relapsed within the follow-up period exhibited reduced orexin levels during the initial withdrawal period; ACTH, but not craving nor cortisol, increased across the abstinence period for successful abstainers but not for relapsers. Sex differences in orexin and craving or withdrawal associations also emerged. Adding sex, HPA hormones, and self-reported measures of craving and withdrawal as potential mediators had minimal effects on the above abstinence and orexin effects. These results provide the first evidence that circulating orexin may be a useful marker of risk for relapse; and sex, adrenal hormones, and self-reported craving and withdrawal were not mediators of this effect. The results point to a promising pathway to investigate objective biological markers for craving and smoking relapse and highlight the complexity of the neurobiology of relapse.",
keywords = "craving, gender, mood, orexin, relapse, smoking",
author = "al'Absi, {Mustafa N} and Lemieux, {Andrine M} and Hodges, {James S} and Allen, {Sharon S}",
year = "2019",
month = "7",
day = "1",
doi = "10.1111/adb.12643",
language = "English (US)",
volume = "24",
pages = "743--753",
journal = "Addiction Biology",
issn = "1355-6215",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Circulating orexin changes during withdrawal are associated with nicotine craving and risk for smoking relapse

AU - al'Absi, Mustafa N

AU - Lemieux, Andrine M

AU - Hodges, James S

AU - Allen, Sharon S

PY - 2019/7/1

Y1 - 2019/7/1

N2 - We examined the extent to which orexin measured during smoking and the early phase of abstinence was related to craving, withdrawal, stress hormones, and risk for smoking relapse in men and women. Considering its role in modulating nicotine-related reward, we predicted that a reduction in circulating orexin during withdrawal would be associated with increased craving and risk for smoking relapse. Two hundred and eighty five participants provided biological samples and self-report information to identify predictors of smoking relapse. All participants attended two laboratory sessions, which were before and after a period of required abstinence from smoking. After quitting, participants also attended four weekly sessions to track smoking relapse. Only smokers who relapsed within the follow-up period exhibited reduced orexin levels during the initial withdrawal period; ACTH, but not craving nor cortisol, increased across the abstinence period for successful abstainers but not for relapsers. Sex differences in orexin and craving or withdrawal associations also emerged. Adding sex, HPA hormones, and self-reported measures of craving and withdrawal as potential mediators had minimal effects on the above abstinence and orexin effects. These results provide the first evidence that circulating orexin may be a useful marker of risk for relapse; and sex, adrenal hormones, and self-reported craving and withdrawal were not mediators of this effect. The results point to a promising pathway to investigate objective biological markers for craving and smoking relapse and highlight the complexity of the neurobiology of relapse.

AB - We examined the extent to which orexin measured during smoking and the early phase of abstinence was related to craving, withdrawal, stress hormones, and risk for smoking relapse in men and women. Considering its role in modulating nicotine-related reward, we predicted that a reduction in circulating orexin during withdrawal would be associated with increased craving and risk for smoking relapse. Two hundred and eighty five participants provided biological samples and self-report information to identify predictors of smoking relapse. All participants attended two laboratory sessions, which were before and after a period of required abstinence from smoking. After quitting, participants also attended four weekly sessions to track smoking relapse. Only smokers who relapsed within the follow-up period exhibited reduced orexin levels during the initial withdrawal period; ACTH, but not craving nor cortisol, increased across the abstinence period for successful abstainers but not for relapsers. Sex differences in orexin and craving or withdrawal associations also emerged. Adding sex, HPA hormones, and self-reported measures of craving and withdrawal as potential mediators had minimal effects on the above abstinence and orexin effects. These results provide the first evidence that circulating orexin may be a useful marker of risk for relapse; and sex, adrenal hormones, and self-reported craving and withdrawal were not mediators of this effect. The results point to a promising pathway to investigate objective biological markers for craving and smoking relapse and highlight the complexity of the neurobiology of relapse.

KW - craving

KW - gender

KW - mood

KW - orexin

KW - relapse

KW - smoking

UR - http://www.scopus.com/inward/record.url?scp=85052623491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052623491&partnerID=8YFLogxK

U2 - 10.1111/adb.12643

DO - 10.1111/adb.12643

M3 - Article

C2 - 30117237

AN - SCOPUS:85052623491

VL - 24

SP - 743

EP - 753

JO - Addiction Biology

JF - Addiction Biology

SN - 1355-6215

IS - 4

ER -